Sugi Predict

Sugi Predict / Targets / RAMP3

RAMP3

Receptor activity-modifying protein 3 (Calcit · O60896 · RAMP3 on Sugi Atlas →

6,126 patent compounds predicted against RAMP3, 3,996 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6176082 SCHEMBL6176082 0.54 17/20
SCHEMBL12428852 SCHEMBL12428852 0.57 16/20
SCHEMBL13356192 SCHEMBL13356192 0.44 16/20
SCHEMBL12984646 SCHEMBL12984646 0.63 15/20
SCHEMBL10066203 SCHEMBL10066203 0.60 15/20
SCHEMBL5315503 SCHEMBL5315503 0.59 15/20
SCHEMBL5315506 SCHEMBL5315506 0.59 15/20
SCHEMBL5578209 SCHEMBL5578209 0.59 15/20
SCHEMBL5578210 SCHEMBL5578210 0.59 15/20
SCHEMBL5311106 SCHEMBL5311106 0.57 15/20
SCHEMBL5311116 SCHEMBL5311116 0.57 15/20
SCHEMBL11116638 SCHEMBL11116638 0.53 15/20
SCHEMBL11116645 SCHEMBL11116645 0.53 15/20
SCHEMBL8624738 SCHEMBL8624738 0.51 15/20
SCHEMBL8624746 SCHEMBL8624746 0.51 15/20
SCHEMBL9081658 SCHEMBL9081658 0.50 15/20
SCHEMBL14096140 SCHEMBL14096140 0.60 14/20
SCHEMBL9292957 SCHEMBL9292957 0.53 13/20
SCHEMBL8973444 SCHEMBL8973444 0.53 13/20
SCHEMBL13120983 SCHEMBL13120983 0.52 13/20

Clinical trials — most relevant to RAMP3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
Improving Outcomes in Neonatal Abstinence Syndrome PHASE3COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone PHASE2COMPLETED
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease PHASE2ACTIVE_NOT_RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron PHASE2COMPLETED
Neuroimmune Effects of Opioid Administration PHASE1COMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Pain Predict Genetics nanRECRUITING
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry nanRECRUITING
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
TAS1R1, TAS1R3, TLR2, TLR4, CA6 Gene Polymorphism on Dental Caries nanCOMPLETED
Stress and Treatment Response in Puerto Rican Children With Asthma nanCOMPLETED
Diet, Genetics, and CVD Risk Factor Response in Blacks nanCOMPLETED
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Transforming Research and Clinical Knowledge in Traumatic Brain Injury nanCOMPLETED
Longitudinal Assessment of Iron Rims in MS Lesions nanRECRUITING
Clinical Characteristics and Pathophysiology of Post-Traumatic Headache nanCOMPLETED
Patient Controlled Analgesia Pharmacogenetic Study nanCOMPLETED
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Characterizing the Role of Pain Sensitivity in Acute to Persistent Low Back Pain nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Family Blood Pressure Program - GENOA nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RAMP3 binder may also engage these)

ProteinNameSimilarity
Q9JJ73 — 0.995 Q9JJ73 →
Q7YS88 — 0.990 Q7YS88 →
Q9WUP1 — 0.985 Q9WUP1 →
Q8R4C4 — 0.973 Q8R4C4 →
RAMP2 Receptor activity-modifying protein 2 (Calcit 0.953 landscape →
Q8R4C5 — 0.952 Q8R4C5 →
Q867C0 — 0.950 Q867C0 →
Q9JJ74 — 0.949 Q9JJ74 →
Q8R143 — 0.939 Q8R143 →
P53801 — 0.938 P53801 →
Q5NVI6 — 0.938 Q5NVI6 →
SPPL2B Signal peptide peptidase-like 2B 0.937 landscape →
Q9WTJ5 — 0.935 Q9WTJ5 →
RAMP1 Receptor activity-modifying protein 1 (Calcit 0.934 landscape →
P97260 — 0.934 P97260 →
Q6P767 — 0.934 Q6P767 →
A2RRU4 — 0.934 A2RRU4 →
Q3TMX7 — 0.934 Q3TMX7 →
SMO Protein smoothened 0.933 landscape →
P97698 — 0.932 P97698 →
Q5MNU5 — 0.932 Q5MNU5 →
Q6NW40 — 0.932 Q6NW40 →
Q7TQ33 — 0.932 Q7TQ33 →
Q6ZRP7 — 0.930 Q6ZRP7 →
Q9NPD7 — 0.929 Q9NPD7 →
Q6GQT6 — 0.929 Q6GQT6 →
Q80UG6 — 0.929 Q80UG6 →
B1ATG9 — 0.929 B1ATG9 →
A6QLK4 — 0.928 A6QLK4 →
A6QM06 — 0.928 A6QM06 →